Cardiometabolic
1.28 billion people have hypertension.
Most of them are managing it alone.
At Newel Health, we develop certified digital medical devices for cardiometabolic disease, built to extend clinical care into daily life, change behavior at scale, and reduce cardiovascular risk where it is most preventable.
The condition
The most common chronic condition in the world.
Still largely uncontrolled.
Hypertension affects 1.28 billion adults globally. It is the single largest modifiable risk factor for cardiovascular disease and premature death, responsible for millions of strokes and heart attacks every year, and approximately 10% of all global healthcare expenditure.
The numbers are stark. Uncontrolled hypertension increases the risk of stroke by four to five times, and the risk of heart attack by two to three times. And yet, of all the people who have been diagnosed, fewer than half receive adequate treatment.
This is not primarily a discovery problem. Hypertension is well understood. The drugs work. The guidelines are clear.
It is a management problem, and it plays out in the 362 days a year when the patient is not in a clinic.
The gap between what is clinically possible and what patients actually experience is enormous. And it is, almost entirely, a gap in continuity.
1.28B
adults globally with hypertension
<50%
receive adequate treatment after diagnosis
4–5×
increased stroke risk from uncontrolled BP
10%
of all global healthcare expenditure
Why current care falls short
Clinical guidelines tell patients what to do.
They do not help them do it every day.
Every day, patients are asked to change habits that have been built over decades. They are asked to eat differently, move more, manage stress better, take treatment consistently, and stay motivated often with only a brief consultation and then months of silence. That is not how lasting change happens. That is not how people feel supported. And that is not how risk is truly managed.
Between visits, patients are often left alone with the hardest part of care: turning medical advice into everyday action. There is no continuous encouragement, no timely feedback, no clear sense of progress, and too often no signal when something begins to slip. For clinicians, the picture is equally incomplete. By the time disengagement or deterioration becomes visible, valuable time has already been lost.
The consequences unfold quietly. Adherence weakens. Motivation fades. Risk builds in the background. And opportunities to intervene earlier, when the course could still be changed, are missed.
Medication is vital, but it cannot carry the full burden of hypertension care on its own. It cannot build habits. It cannot sustain motivation. It cannot create the day to day connection, accountability, and continuity that long term management requires.
What has been missing is not better advice. It is a way to help people live that advice every day.
Our work in cardiometabolic
Our contribution to this space.
Cardiometabolic conditions are among the strongest opportunities in digital therapeutics. They are widespread, behavior driven, and costly when left unmanaged. What has been missing is not clinical logic, but the infrastructure to turn it into continuous care.
Newel Health's work in cardiometabolic disease is anchored by Amicomed, a CE MDR Class IIa certified digital therapeutic for hypertension management, powered by the Pascal algorithm. Amicomed translates continuous blood pressure data into personalised, evidence-based lifestyle coaching, helping patients reduce their cardiovascular risk through structured behavioral intervention and remote monitoring.
Validated across more than 170,000 measurements and 2,800 subjects, Amicomed demonstrated a mean reduction in systolic blood pressure of ~7.9 mmHg in uncontrolled hypertensive patients, a 50% increase in patients reaching ideal blood pressure, and a 30% reduction in major adverse cardiovascular events. It is currently in commercial deployment in Italy, with further expansions underway.
Beyond hypertension, Newel has pipeline assets in development for heart failure and obesity, extending the same platform and behavioral infrastructure into adjacent cardiometabolic conditions.
Learn more about Amicomed →Amicomed
NWL-001 · Commercial pilots active in Italy
~7.9 mmHg
mean systolic BP reduction
+50%
patients reaching ideal BP
−30%
major adverse cardiovascular events
170K+
measurements validated
Certified software and validated intelligence
Behavioral support in daily life
Real world evidence of outcomes
Continuous BP monitoring and coaching
Remote monitoring for proactive care
Building in cardiometabolic? Let's talk.
Whether you are a pharmaceutical company exploring digital companions for a cardiovascular or metabolic asset, a health system seeking to extend hypertension care beyond the clinic, or a device manufacturer looking for certified software to complement your hardware, Newel Health offers the regulatory infrastructure, validated algorithms, and behavioral science expertise to build with you.